Rapid Communication
Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Apr 21, 2008; 14(15): 2434-2439
Published online Apr 21, 2008. doi: 10.3748/wjg.14.2434
Table 1 Demographic characteristics of the patients at entry (mean ± SD)
GroupGroup FOGroup SOt or χ2P
(n = 20)(n = 21)
Age (yr)55.80 ± 10.1059.19 ± 10.611.0470.3
Weight (kg)63.50 ± 8.8665.40 ± 9.200.6750.5
Height (cm)164.55 ± 6.68165.29 ± 7.600.3290.74
BMI23.38 ± 2.3823.92 ± 2.840.6550.52
Gender (male/female)10/1015/61.9770.16
Diagnosis
(colon cancer/rectal cancer)11/912/90.0190.89
TNM stage
Stage I033.20.21
Stage II1010
Stage III108
Table 2 Regimen of daily TPN in the FO and SO groups/kg body weight (g)
DayBoth groups
SO + FO lipidsSO lipids
GlucoseNitrogen
POD+13.00.180.5 SO + 0.1 FO0.6 SO
POD+2-POD+73.00.181.0 SO + 0.2 FO1.2 SO
Table 3 Counts of white blood cells, platelets, and γ-glutamyltranspeptidase before and after operation in the FO group versus the SO group (mean ± SD)
GroupnWBC (× 109)
Plt (× 109)
r-GT (U/L)
POD-1POD+1POD+81POD-1POD+1POD+81POD-1POD+1POD+81
FO206.76 ± 2.0111.20 ± 2.318.17 ± 1.37-3.03 ± 2.46241.93 ± 56.62181.50 ± 73.47262.72 ± 58.6381.22 ± 61.5823.30 ± 11.5514.30 ± 9.2637.20 ± 24.4922.90 ± 21.35
SO217.03 ± 2.5911.70 ± 3.329.03 ± 2.58-2.67 ± 2.58221.51 ± 44.20176.51 ± 41.25264.60 ± 74.1388.08 ± 67.0717.43 ± 5.8012.76 ± 7.8948.48 ± 28.4135.71 ± 25.34
t0.3810.5671.3220.4471.2900.2700.0900.3412.0720.5741.3581.747
P0.710.570.190.660.200.790.930.740.050.570.180.09
Table 4 Assessment of inflammatory and immunological parameters before and after operation in the FO group versus the SO group (mean ± SD)
GroupnIL-6 (pg/mL)
TNF-α(pg/mL)
POD-1POD+1POD+812POD-1POD+1POD+812
FO209.02 ± 23.2559.66 ± 31.9115.23 ± 8.4250.64 ± 32.21-44.43 ± 30.532.74 ± 2.003.31 ± 2.852.49 ± 2.060.57 ± 3.46-0.82 ± 2.71
SO2110.42 ± 10.7542.60 ± 50.1234.21 ± 44.1232.18 ± 47.69-8.39 ± 69.082.48 ± 3.732.66 ± 2.762.94 ± 3.120.18 ± 4.500.27 ± 1.67
t0.2491.2921.9351.4452.1410.2700.7380.5440.3121.570
P0.8040.2040.0660.1560.0390.7890.4650.5900.7570.125
Table 5 Assessment of inflammatory and immunological parameters before and after operation in the FO group versus the SO group (mean ± SD)
GroupnCD8+(%)
Ratio of CD4+/CD8+
POD-1POD+1POD+812POD-1POD+1POD+812
FO2025.89 ± 8.0928.87 ± 7.6325.46 ± 7.202.99 ± 7.20-3.41 ± 5.791.54 ± 0.790.89 ± 0.521.80 ± 0.74-0.65 ± 0.690.92 ± 0.62
SO2126.12 ± 10.9526.50 ± 12.0826.31 ± 9.850.38 ± 13.07-0.19 ± 10.121.32 ± 0.501.27 ± 1.341.52 ± 0.69-0.05 ± 1.280.25 ± 1.22
t0.0790.7470.3160.7861.2441.0671.1951.2691.8542.186
P0.9370.4600.7540.4370.2210.2930.2390.2120.0710.035
Table 6 Assessment of inflammatory and immunological parameters before and after operation in the FO group versus the SO group (mean ± SD)
Groupn CD3+ (%)
CD4+ (%)
POD-1POD+1POD+812POD-1POD+1POD+812
FO2065.81 ± 9.5256.43 ± 12.5769.28 ± 9.42-9.38 ± 9.8812.85 ± 11.6135.69 ± 11.4823.68 ± 10.6941.48 ± 9.51-12.02 ± 10.7917.80 ± 10.86
SO2157.41 ± 11.1159.73 ± 16.0663.57 ± 10.262.32 ± 20.363.84 ± 19.6230.46 ± 9.7424.41 ± 15.8734.07 ± 10.17-6.05 ± 17.959.66 ± 17.55
t2.5910.7311.8512.3201.7991.5750.1732.4051.2811.775
P0.0130.4690.0720.0260.0810.1230.8640.0210.2080.084